Introduction
Kaposi's sarcoma herpesvirus is a member of the γ 2 subfamily of herpesviruses and the causative agent of Kaposi's sarcoma 1, 2 . The KSHV genome has been found in the cells of two
B-cell lymphoproliferative diseases: primary effusion lymphoma (PEL) and Multicentric
Castleman's disease (MCD) and is associated with two inflammatory syndromes, immune reconstitution inflammatory syndrome-KS (IRIS-KS) and KSHV inflammatory cytokine syndrome (KICS) [3] [4] [5] . KSHV has been classified as a Group 1 carcinogen by the International Agency for
Research on Cancer and the National Toxicology Program 14 th Report on Carcinogens 6 .
The KSHV genome contains several viral homologs of cellular genes, many of which promote immune evasion, cell survival and proliferation. KSHV exists mostly as a latent infection, where the viral genome is tethered to the host chromosome by LANA and infectious virions are not produced. Nascent virions are produced during periods of lytic replication induced by expression of the viral transactivator, RTA 7 .
KSHV oncogenesis is, in part, attributed to genes expressed during latency. Viral FLICE inhibitory protein (vFLIP or K13), is a latently expressed gene that was originally identified as an inhibitor of apoptosis, due to the presence of tandem death effector domains 8, 9 . vFLIP is a potent activator of NFκB signaling and this activity is dependent on interaction with IKKߛ [10] [11] [12] .
vFLIP has also been shown to promote NFκB signaling through upregulation of IKKߝ and CADM1 and inhibition of the SAP18/HDAC1 complex resulting in activation of NFκB via acetylation of p65 [13] [14] [15] . NFκB signaling is required for the virus to maintain latency, as chemical inhibition of this signaling pathway has been shown to promote lytic replication 16, 17 .
vFLIP plays a role in oncogenesis and genome instability. A transgenic mouse model of vFLIP expression displays persistent NFκB activation and an increased incidence of lymphoma as well as B cell abnormalities similar to those observed in MCD (reviewed in 18 ). More recently, vFLIP was shown to increase LINE-1 retrotransposition which may promote genome instability 19 .
NF-κB signaling induces expression of negative regulators that limit the inflammatory response.
A20 (TNFAIP3), one such negative regulator of NFκB, is induced by vFLIP. A20 is a ubiquitin editing protein with both C-terminal ubiquitin ligase activity and N-terminal deubiquitinase activity. In one well characterized mechanism, A20 forms a ubiquitin editing complex with Itch, RNF11, and TAX1BP1, and downmodulates NFκB signaling through removal of K63-linked polyubiquitin chains from RIPK1 followed by addition of K48-linked polyubiquitin chains, resulting in degradation of RIPK1 via the proteasome. A20 is reported to deubiquitinate a number of signaling intermediates within the NFκB pathway in addition to RIPK1, including IKKߛ, TRAF6, TRAF2 and MALT1 [20] [21] [22] .
We previously reported that RTA induces the degradation of vFLIP early in lytic reactivation resulting in the termination of NFκB signaling, presumably to promote transition from latency to lytic replication 23 . RTA induced degradation of vFLIP is dependent on the activity of the Itch ubiquitin ligase 24 . We identified mutants of vFLIP that are unable to interact with Itch and cannot activate NFκB. Here we report that vFLIP interacts with the A20/Itch ubiquitin editing complex and this interaction occurs independently of RTA. We propose that vFLIP inhibits A20 DUB activity thereby modulating NFκB signaling through interference with negative regulation. We demonstrate reduced A20 activity and increased levels of RIPK1K ubiquitin conjugates following stimulation with TNFA in the presence of vFLIP. (Fig. 2a) . We evaluated additional Itch and/or A20 substrates, RIPK1 and c-Jun, by immunoblot and observed a modest decrease in protein levels compared to the internal tubulin control (Fig. 2b ).
To further examine the effect of RTA on the ubiquitination of Itch and A20 substrates, we conducted an analysis of the ubiquitinated proteome in SILAC labeled RTA transfected 293T cells using the anti-diglycine remnant (K-ε-GG) antibody. We identified 193 ubiquitination sites with differential ubiquitination in 146 proteins (Fig. 2c) . We detected two known Itch or A20
substrates that exhibited a significant increase in ubiquitination in the presence of RTA. We observed a 1.5-fold increase in the ubiquitination of BRAT1, a known Itch substrate, and a nearly 3-fold increase in ubiquitinated UBE2N, a known A20 substrate, in RTA transfected cells compared to empty vector transfected controls (Fig. 2d ). Taken together, this data suggests that while RTA may play a role in the alteration of the ubiquitome, and perhaps activation of the Itch ubiquitin ligase or Itch/A20 ubiquitin editing complex, the exact mechanism remains unclear.
vFLIP inhibits the debiquitinase activity of A20
A20 is a well characterized negative regulator of NFκB signaling. Following stimulation of NFκB via the TNF receptor (TNFR), A20 downregulates signaling through removal of K63 linked polyubiquitin chains from RIPK1 and in concert with Itch, adds K48 linked polyubiquitin, resulting in RIPK1 degradation via the proteasome. It was previously reported that vFLIP induces the expression of A20. It has been proposed that A20 expression, in the context of latent KSHV infection, is necessary to limit the inflammatory phenotype induced by persistent NFκB signaling. We hypothesized that A20 activity needs to be tightly regulated, as excessive activity has the potential interfere with latency and cell survival, and inhibition of NFκB signaling has been shown to promote apoptosis and lytic reactivation. To this end, we assessed the impact of vFLIP on A20 DUB activity. Using purified K63-linked tetraubiquitin, A20 and vFLIP, we evaluated A20 DUB activity via in vitro assay. Addition of purified A20 alone to tetraubiquitin, resulted in cleavage of tetraubiquitin to faster migrating mono and polyubiquitin species (Ub-3, Ub-2, Ub-1), however addition of recombinant vFLIP resulted in a dose dependent decrease in DUB activity (Fig. 3a) .
A well characterized target of A20 DUB activity is RIPK1, following TNFR stimulation. minutes of TNFA treatment, followed by deubiquitination 2h post treatment (Fig. 3b) . Addition of vFLIP, however, resulted in detection of sustained RIPK1 ubiquitin conjugates, which was accentuated in cells transfected with K63-only ubiquitin (Fig. 3b) . These data, taken together, suggest that vFLIP has an inhibitory effect on A20 DUB activity.
vFLIP has a SUMO interaction motif (SIM)
PML nuclear bodies have been implicated in antiviral defense, apoptosis, and the DNA damage response as well as other cellular processes. They are known to be highly modified by the small ubiquitin-like modifier SUMO. In our initial vFLIP studies, we observed vFLIP colocalization with PML via immunofluorescence assay, prompting the question as to whether vFLIP has a SIM (unpublished observation). Analysis of the vFLIP protein sequence resulted in the identification of a putative tandem SIM spanning amino acids V21-VLFLLN-V28 based on the following (Fig. 4a) . Indeed, wild-type vFLIP was able to bind recombinant SUMO 1 and SUMO 2/3, albeit to a lesser extent, while mutant vFLIP V22E, was no longer able to bind to either SUMO 1 or 2/3 ( Fig. 4b) .
We previously reported that this vFLIP mutant was resistant to RTA induced degradation and was unable to activate NFκB, suggesting that this SIM is important for interaction with components of the NFκB signaling pathway and RTA 23, 24 . We previously reported that vFLIP V22E is unable to interact with the Itch ubiquitin ligase 24 . To determine whether Itch and A20 are SUMOylated, we immunoprecipitated FLAG tagged Itch or A20 and probed the 500mM NaCl washed immunoprecipitates with antibody against endogenous SUMO 1 or SUMO 2/3. We observed corresponding SUMO 1 and 2/3 bands in the Itch immunoprecipitates (Fig. 4c) . Taken together, these results suggest that vFLIP may interact with the Itch/A20 ubiquitin editing complex via a SUMO dependent mechanism as the SIM mutant vFLIP V22E cannot interact with Itch nor activate NFκB and Itch is modified by SUMO 1 and 2/3.
Small molecule inhibition of SUMOylation increases production of infectious virus
Our phenotype for which this gene is named. A20 -/-mice also display a phenotype associated with inflammation and autoimmunity, exhibiting hypersensitivity to TNF and premature death. To establish and maintain a latent infection, vFLIP must activate NFκB and signaling must be sustained without killing the host and to accomplish this, the virus must control negative regulators of NFκB.
We observed interaction of vFLIP with the Itch and A20 ubiquitin editing complex. We previously reported that in the presence of RTA, Itch targets vFLIP for degradation. These observations suggest that vFLIP may be interacting with the Itch/A20 ubiquitin editing complex in latency and reactivation along with expression of RTA may be modulating the activity of this complex. We evaluated multiple known substrates of Itch via western blot and proteomic analysis and observed modest decreases in protein levels when RTA was expressed suggesting that RTA is altering Itch substrate stability. Our proteomics data revealed identification of 146 proteins with RTA dependent alterations in ubiquitination, however only two were known Itch or A20
substrates, suggesting that while RTA has a demonstrated effect on the cellular ubiquitome, the mechanism(s) governing this observation remains unclear.We reasoned that vFLIP interaction with the Itch A20 ubiquitin editing complex may function to promote NFκB signaling and expression of RTA abrogates signaling by inducing the degradation of vFLIP as well as other members of the complex.
vFLIP had no effect on Itch/A20 complex assembly, suggesting that vFLIP was not inhibiting protein complex formation as had been described with HTLV Tax 25 . We observed, through in vitro assay and through immunoprecipitation of RIPK1 conjugates, inhibition of A20 DUB activity by vFLIP. Detection of sustained K63 ubiquitinated RIP1 in the presence of vFLIP, suggests that A20 DUB activity is limited thereby allowing for sustained NFKB signaling.
We identified a SIM in vFLIP and observed interaction with SUMO-1 and 2/3. We previously reported that this motif is required for activation of NFKB, degradation of vFLIP by RTA and interaction with Itch. Taken together these data suggest that vFLIP interacts with the Itch/A20 complex via a SUMO dependent mechanism. We observed evidence of Itch SUMOylation and inhibition of global SUMOylation resulted in a dose dependent increase in infectious virus production.
Methods

Cell Line Maintenance and Transfection
Human Embryonic Kidney 293T (HEK 293T) cells were cultured in DMEM medium supplemented with 10% Fetal Bovine Serum and were grown at 5% CO 2 at 37°C. Cells were transfected at 60-70% confluency using 1µg/mL polyethyleneimine (PEI) linear, MW~25,000
(Polysciences, Inc. Cat#23966) at a ratio of 1µg plasmid DNA: 3µl PEI. After 5 min of incubation the mixture was added to the cells. 24h post transfection the media was changed and if appropriate, 2.5µM of MG132 was added. Vero rKSHV.294 cells containing a recombinant reporter KSHV clone were cultured in DMEM, 10% FBS, and 10 μg/ml G418 antibiotic. MSR-tet OFF 293T cells were cultured in DMEM and 10% FBS.
Reagents, Plasmids, and Antibodies
The proteasome inhibitor MG132 (Boston Biochem) was used in this study. FLAG-A20, 
Immunoblot Analysis
Proteins were run on 12% Tris-Glycine or Any kD mini-PROTEAN Precast Gel (Biorad)
with Tris-glycine running buffer. The proteins were then transferred to a PVDF membrane using semi-dry transfer system at 20V for 20 minutes. The membranes were blocked in 5% non-fat dry milk in PBS for one hour. Primary antibodies were diluted in with 2.5% non-fat dry milk at 1uL antibody: 1000uL milk and applied to the membranes. The membranes were incubated on a shaker at 4°C overnight and were washed in PBS with 0.1% Tween the following day.
Secondary antibodies were applied to the membranes in 2.5% non-fat dry milk at 1uL antibody:
1000uL milk. The membranes were incubated at room temperature on a shaker for one hour and afterward were washed with PBS and 0.1% Tween. Proteins were visualized with the addition of ECL substrate and the detection of the luminescence on x-ray film or scanned by a
Li-COR C-DiGit Blot Scanner.
Immunoprecipitation
Transfected cells with appropriate constructs were harvested 48h post-transfection with PBS and centrifuged at 1500 rpm for 10 min. The PBS was removed and 1mL of lysis buffer with 10µl of a protease inhibitor cocktail kit (Thermo Scientific) were added to each cell pellet.
When appropriate 12.5µL of 5 mM NEM was added to each cell pellet. Cell lysates were centrifuged at 10,000 rpm for 5 minutes to remove cell debris. The resulting supernatant was precleared with protein A/G PLUS-agarose (Santa Cruz) for 30 min at 4°C. The lysates were transferred to a new 1.5mL tube and protein concentrations were measured and normalized with a Pierce BCA protein assay kit. Approximately 50 µg of protein was transferred to new 1.5mL tube to serve as control lysate. 1μg of the appropriate primary antibody was added to the remaining cell lysate and incubated on a rotator overnight at 4°C. 25µL of protein A/G-agarose were added the following day for 1hr and washed 4x with RIPA lysis buffer. 50µl of 2X Laemmli
Buffer were added and samples were boiled at 100°C for 10 min. Samples were visualized through immunoblot analysis as described above A20 purification A20-FLAG was transfected into 293T cells, and purified following 48 hours incubation. Nine 10 cm dishes of A20 transfected cells were harvested in ice cold PBS, centrifuged, and lysed in 1 mL 50 mM HEPES, pH 7.4, 100 mM KAc, 5 mM MgAc2, 100 μ g/mL digitonin, 1 mM DTT, 1X
GST-Pull-down Assay
EDTA-free Complete protease inhibitor cocktail (Thermo Scientific) for 20 min on ice. The lysate was centrifuged to remove cell debris. Supernatant was incubated with 100 μ L of anti-Flag affinity resin (Sigma) for 1-1.5 hr at 4°C. The resin was washed three times in 1 mL lysis buffer, three times in 1 mL 50 mM HEPES, pH 7.4, 400 mM KAc, 5mM MgAc2, 100 μ g/mL digitonin, 1 mM DTT buffer, and three times in 50 mM HEPES,pH 7.4, 100 mM KAc, 5 mM MgAc2 buffer.
Elutions were carried out with one volume of 0.2 mg/ml 3X-Flag peptide in the final wash buffer at room temperature for 30 min. Two sequential elutions were combined to form the final fraction.
In vitro deubiquitination assay
V5-His tagged vFLIP was expressed in E. coli (BL21) and purified using Ni-NTA resin (ThermoFisher). A20-Flag was purified as previously described. Purified tetra-K63 ubiquitin was purchased from Boston Biochem. The following reagents were added to 20μl reactions where indicated: A20 (2μM), vFLIP (1μM, 5μM, 10μM), tetra-K63 Ub (500nM). Reactions were incubated at 37ºC for 2hrs followed by the addition of 4x Laemmli loading buffer. Reactions were analyzed by SDS PAGE followed by immunoblot. 
